Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

RANKL-induced osteoclastogenesis in bone marrow-derived macrophages is suppressed by cisapride.

Park KR, Yun HM.

Toxicology. 2019 Jun 15;422:95-101. doi: 10.1016/j.tox.2019.05.010. Epub 2019 May 28.

PMID:
31150804
2.

RANKL-induced osteoclastogenesis is suppressed by 4-O-methylhonokiol in bone marrow-derived macrophages.

Park KR, Kim JY, Kim EC, Yun HM, Hong JT.

Arch Pharm Res. 2017 Aug;40(8):933-942. doi: 10.1007/s12272-017-0932-z. Epub 2017 Jul 24.

PMID:
28736799
3.

Macrolactin F inhibits RANKL-mediated osteoclastogenesis by suppressing Akt, MAPK and NFATc1 pathways and promotes osteoblastogenesis through a BMP-2/smad/Akt/Runx2 signaling pathway.

Li L, Sapkota M, Gao M, Choi H, Soh Y.

Eur J Pharmacol. 2017 Nov 15;815:202-209. doi: 10.1016/j.ejphar.2017.09.015. Epub 2017 Sep 15.

PMID:
28919027
4.

Leonurine hydrochloride inhibits osteoclastogenesis and prevents osteoporosis associated with estrogen deficiency by inhibiting the NF-κB and PI3K/Akt signaling pathways.

Yuan FL, Xu RS, Jiang DL, He XL, Su Q, Jin C, Li X.

Bone. 2015 Jun;75:128-37. doi: 10.1016/j.bone.2015.02.017. Epub 2015 Feb 21.

PMID:
25708053
6.

Calcitonin-gene-related peptide stimulates stromal cell osteogenic differentiation and inhibits RANKL induced NF-kappaB activation, osteoclastogenesis and bone resorption.

Wang L, Shi X, Zhao R, Halloran BP, Clark DJ, Jacobs CR, Kingery WS.

Bone. 2010 May;46(5):1369-79. doi: 10.1016/j.bone.2009.11.029. Epub 2009 Dec 2.

8.

Agelasine D suppresses RANKL-induced osteoclastogenesis via down-regulation of c-Fos, NFATc1 and NF-κB.

Kang MR, Jo SA, Yoon YD, Park KH, Oh SJ, Yun J, Lee CW, Nam KH, Kim Y, Han SB, Yu J, Rho J, Kang JS.

Mar Drugs. 2014 Nov 24;12(11):5643-56. doi: 10.3390/md12115643.

9.

CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo.

Kim JY, Min JY, Baek JM, Ahn SJ, Jun HY, Yoon KH, Choi MK, Lee MS, Oh J.

Bone. 2015 Oct;79:242-51. doi: 10.1016/j.bone.2015.06.011. Epub 2015 Jun 21.

PMID:
26103094
10.

Poligoni Multiflori Radix enhances osteoblast formation and reduces osteoclast differentiation.

Han SY, Lee KH, Kim YK.

Int J Mol Med. 2018 Jul;42(1):331-345. doi: 10.3892/ijmm.2018.3603. Epub 2018 Mar 30.

11.

Methylsulfonylmethane Inhibits RANKL-Induced Osteoclastogenesis in BMMs by Suppressing NF-κB and STAT3 Activities.

Joung YH, Darvin P, Kang DY, Sp N, Byun HJ, Lee CH, Lee HK, Yang YM.

PLoS One. 2016 Jul 22;11(7):e0159891. doi: 10.1371/journal.pone.0159891. eCollection 2016.

12.

Coenzyme q10 regulates osteoclast and osteoblast differentiation.

Moon HJ, Ko WK, Jung MS, Kim JH, Lee WJ, Park KS, Heo JK, Bang JB, Kwon IK.

J Food Sci. 2013 May;78(5):H785-891. doi: 10.1111/1750-3841.12116. Epub 2013 Apr 12.

PMID:
23582186
13.

Jolkinolide B inhibits RANKL-induced osteoclastogenesis by suppressing the activation NF-κB and MAPK signaling pathways.

Ma X, Liu Y, Zhang Y, Yu X, Wang W, Zhao D.

Biochem Biophys Res Commun. 2014 Mar 7;445(2):282-8. doi: 10.1016/j.bbrc.2014.01.145. Epub 2014 Jan 31.

PMID:
24491533
14.

Hispidulin attenuates bone resorption and osteoclastogenesis via the RANKL-induced NF-κB and NFATc1 pathways.

Nepal M, Choi HJ, Choi BY, Yang MS, Chae JI, Li L, Soh Y.

Eur J Pharmacol. 2013 Sep 5;715(1-3):96-104. doi: 10.1016/j.ejphar.2013.06.002. Epub 2013 Jun 19.

PMID:
23791609
15.
16.

Inhibition of receptor activator of nuclear factor-κB ligand- or lipopolysaccharide-induced osteoclast formation by conophylline through downregulation of CREB.

Koide N, Kondo Y, Odkhuu E, Ulziisaikhan J, Ukaji T, Yokochi T, Umezawa K.

Immunol Lett. 2014 Sep;161(1):31-7. doi: 10.1016/j.imlet.2014.04.006. Epub 2014 May 2.

PMID:
24792671
17.

Matrine prevents bone loss in ovariectomized mice by inhibiting RANKL-induced osteoclastogenesis.

Chen X, Zhi X, Pan P, Cui J, Cao L, Weng W, Zhou Q, Wang L, Zhai X, Zhao Q, Hu H, Huang B, Su J.

FASEB J. 2017 Nov;31(11):4855-4865. doi: 10.1096/fj.201700316R. Epub 2017 Jul 24.

18.

Emodin regulates bone remodeling by inhibiting osteoclastogenesis and stimulating osteoblast formation.

Kim JY, Cheon YH, Kwak SC, Baek JM, Yoon KH, Lee MS, Oh J.

J Bone Miner Res. 2014 Jul;29(7):1541-53. doi: 10.1002/jbmr.2183.

19.

Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.

Li C, Yang Z, Li Z, Ma Y, Zhang L, Zheng C, Qiu W, Wu X, Wang X, Li H, Tang J, Qian M, Li D, Wang P, Luo J, Liu M.

J Bone Miner Res. 2011 Mar;26(3):644-56. doi: 10.1002/jbmr.242.

Supplemental Content

Support Center